Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study
Open Access
- 17 October 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Hypertension Research
- Vol. 45 (1), 106-115
- https://doi.org/10.1038/s41440-021-00752-9
Abstract
Hyperuricemia is related to an increased risk of cardiovascular events from a meta-analysis and antihyperuricemia agents may influence to cardiac function. We evaluated the effect of febuxostat on echocardiographic parameters of diastolic function in patients with asymptomatic hyperuricemia as a prespecified endpoint in the subanalysis of the PRIZE study. Patients in the PRIZE study were assigned randomly to either add-on febuxostat treatment group or control group with only appropriate lifestyle modification. Of the 514 patients in the overall study, 65 patients (31 in the febuxostat group and 34 in the control group) who had complete follow-up echocardiographic data of the ratio of peak early diastolic transmitral flow velocity (E) to peak early diastolic mitral annular velocity (e′) at baseline and after 12 and 24 months were included. The primary endpoint was a comparison of the changes in the E/e′ between the two groups from baseline to 24 months. Interestingly, e′ was slightly decreased in the control group compared with in the febuxostat group (treatment p = 0.068, time, p = 0.337, treatment × Time, p = 0.217). As a result, there were significant increases in E/e′ (treatment p = 0.045, time, p = 0.177, treatment × time, p = 0.137) after 24 months in the control group compared with the febuxostat group. There was no significant difference in the serum levels of N-terminal-pro brain natriuretic peptide and high-sensitive troponin I between the two groups during the study period. In conclusions, additional febuxostat treatment in patients with asymptomatic hyperuricemia for 24 months might have a potential of preventable effects on the impaired diastolic dysfunction.Keywords
This publication has 31 references indexed in Scilit:
- Impact of Gout on Left Atrial Function: A Prospective Speckle-Tracking Echocardiographic StudyPLOS ONE, 2014
- Allopurinol Acutely Increases Adenosine Triphospate Energy Delivery in Failing Human HeartsJournal of Invasive Cardiology, 2012
- Hyperuricemia and the Echocardiographic Measures of Myocardial DysfunctionCongestive Heart Failure, 2011
- Uric Acid as a Predictor of All-Cause Mortality in Heart Failure: A Meta-AnalysisCongestive Heart Failure, 2011
- Uric Acid and Cardiovascular RiskThe New England Journal of Medicine, 2008
- Serum Uric AcidJournal of the American Society of Nephrology, 2006
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyJournal of the American Society of Echocardiography, 2005
- Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and GoutThe New England Journal of Medicine, 2005
- Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemiaAmerican Heart Journal, 2004
- Relation Between Serum Uric Acid and Risk of Cardiovascular Disease in Essential HypertensionHypertension, 2000